Predictors for overall survival
Predictor . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Univariate | ||
| Troponin T greater than or equal to 0.035 μg/L | 4.4 (1.7-10.9) | .002 |
| Troponin I greater than or equal to 0.1 μg/L | 4.9 (1.6-15.1) | .006 |
| NT-proBNP greater than or equal to 332 ng/L | 3.8 (1.2-12) | .02 |
| cTnT Idealized Risk Score* | 2.2 (1.4-3.3) | .0003 |
| cTnI Idealized Risk Score† | 2.8 (.8-9.4) | .09 |
| cTnT/NT-proBNP stage‡ | 3.1 (1.5-6.2) | .001 |
| cTnI/NT-proBNP stage‡ | 3.8 (1.7-8.4) | .001 |
| β2-microglobulin greater than 2.7 U/L | 3.8 (1.5-9.5) | .004 |
| Organ systems involved, no. | 3.5 (1.9-6.5) | < .0001 |
| Serum creatinine | 2.3 (1.0-5.5) | .05 |
| Melphalan intensity, high dose | 0.5 (0.2-1.1) | .08 |
| Left ventricular EF less than or equal to 50% | 1.4 (0.3-6) | .7 |
| IVS greater than or equal to 15 mm | 1.8 (0.6-5.0) | .3 |
| Age greater than 60 y | 1.0 (0.4-2.5) | .99 |
| Female gender | 1.2 (0.5-2.9) | .7 |
| Time to transplantation | 0.8 (0.8-1.0) | .06 |
| Serum M spike | 1.0 (0.5-1.9) | .99 |
| Bone marrow plasmacytosis less than 30% | 1.1 (0.1-8.4) | .9 |
| Bone marrow plasma cell labeling index | 1.9 (0.8-4.2) | .1 |
| Multivariate model 1 | ||
| cTnT/NT-proBNP stage | 2.3 (1.1-4.7) | .02 |
| β2-microglobulin, U/L | 2.4 (1.5-3.8) | .0005 |
| Multivariate model 2 | ||
| cTnI/NT-proBNP stage | 3.2 (1.4-7.4) | .007 |
| β2 microglobulin, U/L | 2.4 (1.4-3.9) | .0006 |
Predictor . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Univariate | ||
| Troponin T greater than or equal to 0.035 μg/L | 4.4 (1.7-10.9) | .002 |
| Troponin I greater than or equal to 0.1 μg/L | 4.9 (1.6-15.1) | .006 |
| NT-proBNP greater than or equal to 332 ng/L | 3.8 (1.2-12) | .02 |
| cTnT Idealized Risk Score* | 2.2 (1.4-3.3) | .0003 |
| cTnI Idealized Risk Score† | 2.8 (.8-9.4) | .09 |
| cTnT/NT-proBNP stage‡ | 3.1 (1.5-6.2) | .001 |
| cTnI/NT-proBNP stage‡ | 3.8 (1.7-8.4) | .001 |
| β2-microglobulin greater than 2.7 U/L | 3.8 (1.5-9.5) | .004 |
| Organ systems involved, no. | 3.5 (1.9-6.5) | < .0001 |
| Serum creatinine | 2.3 (1.0-5.5) | .05 |
| Melphalan intensity, high dose | 0.5 (0.2-1.1) | .08 |
| Left ventricular EF less than or equal to 50% | 1.4 (0.3-6) | .7 |
| IVS greater than or equal to 15 mm | 1.8 (0.6-5.0) | .3 |
| Age greater than 60 y | 1.0 (0.4-2.5) | .99 |
| Female gender | 1.2 (0.5-2.9) | .7 |
| Time to transplantation | 0.8 (0.8-1.0) | .06 |
| Serum M spike | 1.0 (0.5-1.9) | .99 |
| Bone marrow plasmacytosis less than 30% | 1.1 (0.1-8.4) | .9 |
| Bone marrow plasma cell labeling index | 1.9 (0.8-4.2) | .1 |
| Multivariate model 1 | ||
| cTnT/NT-proBNP stage | 2.3 (1.1-4.7) | .02 |
| β2-microglobulin, U/L | 2.4 (1.5-3.8) | .0005 |
| Multivariate model 2 | ||
| cTnI/NT-proBNP stage | 3.2 (1.4-7.4) | .007 |
| β2 microglobulin, U/L | 2.4 (1.4-3.9) | .0006 |
EF indicates ejection fraction; IVS, interventricular septum.
See “Patients and methods” for equation. If risk levels 3 through 5 are collapsed into one level: HR 3.8, 95% CI 1.5-9.6, P = .004.
See “Patients and methods” for equation. If levels 2 and 3 are collapsed into one level: HR 6.6, 95% CI .9-49.6, P = .07.
Stage I is when troponin (either cTnT or cTnI) and NT-proBNP are both below threshold. Stage II is when troponin (either cTnT or cTnI) or NT-proBNP is greater than or equal to threshold value. Stage III is when troponin (either cTnT or cTnI) and NT-proBNP are both greater than or equal to threshold value. Threshold values for cTnT, cTnI, and NT-proBNP are < 0.035 μg/L, < 0.1 μg/L, and < 332 ng/L. Suffix (-t or -i) used depending on whether the troponin measured is cTnT or cTnI.